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Abstract
Background
China accounted for 87% (9.8 million/11.3 million) of all hand, foot, and mouth disease
(HFMD) cases reported to WHO during 2010–2014. Enterovirus 71 (EV71) is responsible
for most of the severe HFMD cases. Three EV71 vaccines recently demonstrated good effi-
cacy in children aged 6–71 mo. Here we assessed the cost-effectiveness of routine pediat-
ric EV71 vaccination in China.
Methods and Findings
We characterized the economic and health burden of EV71-associated HFMD (EV71-
HFMD) in China using (i) the national surveillance database, (ii) virological surveillance rec-
ords from all provinces, and (iii) a caregiver survey on the household costs and health utility
loss for 1,787 laboratory-confirmed pediatric cases. Using a static model parameterized
with these data, we estimated the effective vaccine cost (EVC, defined as cost/efficacy or
simply the cost of a 100% efficacious vaccine) below which routine pediatric vaccination
would be considered cost-effective. We performed the base-case analysis from the societal
perspective with a willingness-to-pay threshold of one times the gross domestic product per
capita (GDPpc) and an annual discount rate of 3%. We performed uncertainty analysis by
(i) accounting for the uncertainty in the risk of EV71-HFMD due to missing laboratory data in
the national database, (ii) excluding productivity loss of parents and caregivers, (iii) increas-
ing the willingness-to-pay threshold to three times GDPpc, (iv) increasing the discount rate
to 6%, and (v) accounting for the proportion of EV71-HFMD cases not registered by national
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surveillance. In each of these scenarios, we performed probabilistic sensitivity analysis to
account for parametric uncertainty in our estimates of the risk of EV71-HFMD and the
expected costs and health utility loss due to EV71-HFMD. Routine pediatric EV71 vaccina-
tion would be cost-saving if the all-inclusive EVC is below US$10.6 (95% CI US$9.7–US
$11.5) and would remain cost-effective if EVC is below US$17.9 (95% CI US$16.9–US
$18.8) in the base case, but these ceilings could be up to 66% higher if all the test-negative
cases with missing laboratory data are EV71-HFMD. The EVC ceiling is (i) 10%–14% lower
if productivity loss of parents/caregivers is excluded, (ii) 58%–84% higher if the willingness-
to-pay threshold is increased to three times GDPpc, (iii) 14%–19% lower if the discount rate
is increased to 6%, and (iv) 36% (95% CI 23%–50%) higher if the proportion of EV71-
HFMD registered by national surveillance is the same as that observed in the three EV71
vaccine phase III trials. The validity of our results relies on the following assumptions: (i)
self-reported hospital charges are a good proxy for the opportunity cost of care, (ii) the cost
and health utility loss estimates based on laboratory-confirmed EV71-HFMD cases are rep-
resentative of all EV71-HFMD cases, and (iii) the long-term average risk of EV71-HFMD in
the future is similar to that registered by national surveillance during 2010–2013.
Conclusions
Compared to no vaccination, routine pediatric EV71 vaccination would be very cost-effec-
tive in China if the cost of immunization (including all logistical, procurement, and adminis-
tration costs needed to confer 5 y of vaccine protection) is below US$12.0–US$18.3,
depending on the choice of vaccine among the three candidates. Given that the annual
number of births in China has been around 16 million in recent years, the annual costs for
routine pediatric EV71 vaccination at this cost range should not exceed US$192–US$293
million. Our results can be used to determine the optimal vaccine when the prices of the
three vaccines are known.
Introduction
Since the 1990s, large epidemics of hand, foot, and mouth disease (HFMD) have occurred
across the Western Pacific region [1–6]. In China, which accounted for 87% (9.8 million/11.3
million) of all HFMD cases reported to WHO during 2010–2014 [7], HFMD epidemics have
been occurring annually since 2007. Between 2008 and 2013, China’s national HFMD surveil-
lance registered around 9 million cases and 2,700 deaths, 90% and 96% of which, respectively,
occurred in children under 5 y [6]. In 2012, HFMD ranked first among all notifiable diseases in
China by both case count and deaths for children under 5 y [8].
Enterovirus 71 (EV71) is a major causative pathogen of HFMD epidemics. In China, EV71
accounted for more than 90% of laboratory-confirmed fatal HFMD cases between 2008 and
2013 [6]. EV71-associated HFMD (EV71-HFMD) causes substantial morbidity and mortality
because effective therapeutic and preventive measures remain elusive. There is no established
antiviral treatment for EV71-HFMD [9]. The prevention measures suggested by WHO are
hand hygiene and social distancing, the efficacy of which are uncertain [10,11].
Three inactivated monovalent EV71 vaccines (each requiring two doses administered 4 wk
apart) manufactured in China were recently shown in phase III trials to be safe and efficacious
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against EV71-HFMD for children aged 6–71 mo [12–14]. Economic evaluation is important in
considering population rollout of any new vaccine [15]. Here we provide such an evaluation
using the best available data comprising (i) national HFMD surveillance, (ii) HFMD virological
surveillance records from all 31 provinces, and (iii) a nationwide caregiver survey on the eco-
nomic costs and health utility loss associated with EV71-HFMD.
Methods
Ethics Statement
Ethical approval (approval number 201417) was acquired from the institutional review board
of the Chinese Center for Disease Control and Prevention. Caregiver survey interviews were
conducted only after verbal informed consent was obtained from a parent or caregiver of the
pediatric patient. In May 2008, HFMD was added to the list of notifiable diseases in China.
According to China’s law on the prevention and treatment of infectious diseases, personal
identifiers should be collected for individual cases with diagnosis of a notifiable disease, for the
purposes of public health surveillance and response. The National Health and Family Planning
Commission of China decided that the collection of individual data for all notifiable diseases,
including HFMD, according to the national surveillance protocol was part of an ongoing public
health response and was thus exempt from institutional review board assessment.
Model
We used a static model to perform a cost-effectiveness analysis (CEA) of routine pediatric
EV71 vaccination in China (i.e., a model with no indirect protection). In a separate study, we
used a time series susceptible–infected–recovered (TSIR) dynamic model to show that trans-
missibility of EV71-HFMD in China is high (with a national average basic reproductive num-
ber of around 27) and that indirect protection from EV71 vaccination is unlikely to be
significant [16]. Herd immunity appears only at very high vaccine coverage levels and hence
can be ignored at the coverage levels considered in our analysis. As such, we have chosen to use
a static model for the CEA because it provides a simple yet very accurate model of the reduc-
tion in EV71-HFMD incidence conferred by routine pediatric EV71 vaccination. S1 Fig shows
that the long-term incidence reduction predicted by the static model is essentially the same as
that predicted by the TSIR dynamic model. See “Indirect Protection Conferred by Vaccination”
in S1 Text for a more detailed explanation of this phenomenon.
Fig 1 summarizes the model structure and parameterization, with further details provided
in “The Model” in S1 Text. We considered only children aged 6 mo to 5 y (60 mo) because (i)
90%, 94%, and 96% of mild, severe, and fatal HFMD cases, respectively, occur in this age group
[6] and (ii) vaccine efficacy has been demonstrated only in those aged 6–71 mo [12–14]. The
life expectancy of each birth cohort was assumed to be 75 y [17].
We assumed that (i) children would be vaccinated 6 mo after birth, with immediate and
constant efficacy ε against EV71-HFMD for at least 5 y, and (ii) conservatively, if vaccinated
children developed EV71-HFMD, the probability of severe outcomes was the same as that for
unvaccinated children. Consequently, the risk of EV71-HFMD in vaccinated children was
reduced by a proportion ε for all levels of severity.
Data
We parameterized the model using the following data.
National HFMD surveillance dataset during 2010–2013 (S1 Data). China’s national
HFMD surveillance system has been described in our previous report [6]. Briefly, the system
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classifies HFMD cases as severe if the patient experiences neurological, respiratory, or cardio-
pulmonary complications; otherwise, cases are classified as mild [6]. Virological surveillance
requires all hospitals to collect specimens for serotyping from (i) all severe and fatal cases and
(ii) the first five mild cases every month. Serotyping results were classified into four categories:
EV71, Coxsackievirus A16 (CA16), other enterovirus (OEV), or test-negative for enteroviruses.
The system, however, does not record test-negative results. While some test-negative cases
could be misdiagnoses (e.g., chicken pox or measles), others could be bona fide EV71-HFMD
cases but with negative test results because of late collection of specimens, poor specimen qual-
ity, or other reasons. To account for the uncertainty regarding the percentage of test-negative
Fig 1. Model structure and parameterization. (A) The static model used in the CEA with vaccine coverage θ and vaccine efficacy ε. (B) A schematic that
describes how the data sources were used to parameterize the model. See S1 Text for more details. QALY, quality-adjusted life year.
doi:10.1371/journal.pmed.1001975.g001
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cases that were EV71-HFMD, we acquired internal laboratory records from all 31 provinces
(below) to supplement our analysis.
Virological surveillance records from all 31 provinces (S1 Data). This dataset contained
the weekly number of EV71, CA16, OEV, and test-negative results in each province from 1 Jan-
uary 2010 to 31 December 2013 (Fig 2A). These records contained no severity information
until 31 December 2012. As such, we considered 19 test-negative scenarios (scenarios A–S in
Fig 2B) that corresponded to assumptions regarding (i) the percentage of test-negative cases
that were mild, (ii) the percentage of test-negative mild cases that were EV71-HFMD, and (iii)
the percentage of test-negative severe/fatal cases that were EV71-HFMD. As shown in Fig 2B,
there were 21 original scenarios, but three of them were identical, hence only 19 unique scenar-
ios. See “Uncertainty in Test-Negative Cases” in S1 Text for details.
Caregiver survey. A telephone survey was conducted of parents or caregivers of children
aged 6 mo to 5 y with laboratory-confirmed HFMD diagnosed between 1 January 2012 and
17 December 2013 as registered by national surveillance (S2 and S3 Data). Information about
the child’s diagnosis and treatment and household expenses, time off work, and quality of life
related to the HFMD episode was obtained from respondents who consented to be inter-
viewed. Health-related quality of life was measured using the EuroQol EQ-5D-3L instrument
(http://www.euroqol.org/). Briefly, we contacted 29,810 parents or caregivers of HFMD
patients, and 3,500 agreed to participate in our survey. Of these, 1,787 were parents or care-
givers of EV71-HFMD patients. The mean total cost of a pediatric EV71-HFMD episode
reported in China was US$233, US$1,173, US$3,279, and US$2,738 for mild outpatient, mild
inpatient, severe, and fatal cases, respectively. The mean quality-adjusted life year (QALY)
loss per episode was 0.0039, 0.0070, 0.0194, and 30.4, respectively. We found little evidence
of associations between costs or QALY loss and patients’ age, sex, or urban residence, so we
stratified costs and QALY loss by case severity and geographical region only. We estimated
the mean cost and QALY loss per episode using the central limit theorem and accounted for
the associated parametric uncertainty in probabilistic sensitivity analysis. See “Survey on
Household Costs and Quality of Life Detriment Associated with EV71-HFMD” in S1 Text
for details.
Burden of Disease
We assumed that without vaccination, the risk of EV71-HFMD at all levels of severity for
future birth cohorts (denoted by Pmild, Psevere, and Pfatal) would be similar to that registered by
national surveillance during 2010–2013. At each level of severity s, Ps comprised the risk of
EV71-HFMD for the corresponding level of severity in each province (Fig 1). See “The Model”
in S1 Text for mathematical details.
Costs and Health Utility Loss Due to EV71-HFMD
The cost of EV71-HFMD per birth, C, was estimated as the weighted sum of the average cost of
mild, severe, and fatal cases (Cmild, Csevere, and Cfatal), where the weights were simply the risk of
mild, severe, and fatal EV71-HFMD (Pmild, Psevere, and Pfatal). The health utility loss attributable
to EV71-HFMD, Q, was estimated analogously from the health utility loss of mild, severe, and
fatal cases (Qmild, Qsevere, and Qfatal). Cost and health utility loss at each level of severity were
discounted according to the age distribution of cases for the corresponding level of severity in
each province. We did not account for adverse events following immunization because such
events in the phase III trials were largely mild and uncommon [12–14]. We excluded produc-
tivity loss due to pediatric premature death because of unresolved debate about the way such
losses should be costed [18]. See “The Model” in S1 Text for details.
Cost-Effectiveness of EV71 Vaccination in China
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Fig 2. Estimating the percentage of mild and severe HFMD cases attributed to EV71 in China. (A) The number of specimens tested and the distribution
of test results in each of the 31 provinces during 2010–2013. (B) Twenty-one scenarios were generated by making assumptions regarding the percentage of
test-negative cases that were mild during 2010–2012 (the first branching point; annotated in red text) and the percentage of test-negative mild and severe/
Cost-Effectiveness of EV71 Vaccination in China
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Cost-Effectiveness
The incremental cost-effectiveness ratio (ICER) of vaccine introduction was calculated as fol-
lows:
ICER ¼ Cost with EV71 vaccination Cost with no vaccination
Health utility with EV71 vaccinationHealth utility with no vaccination
¼ Vaccine cost ðVaccine efficacyÞ  ðCost due to EV71HFMD per birthÞðVaccine efficacyÞ  ðHealth utility lost due to EV71HFMD per birthÞ
¼ ðVaccine costÞ=ðVaccine efficacyÞ  ðCost due to EV71HFMD per birthÞ
Health utility lost due to EV71HFMD per birth
¼ EVC C
Q
ð1Þ
where vaccine cost was the cost per child fully vaccinated, which included the procurement,
logistical, and administration cost for the necessary number of vaccine doses to confer 5 y of
protection. Because the three EV71 vaccines have signiﬁcantly different efﬁcacy estimates [12–
14] and reliable estimates of their costs are not yet available, we used effective vaccine cost
(EVC), deﬁned as (vaccine cost)/(vaccine efﬁcacy), which is simply the cost adjusted for efﬁ-
cacy, or the cost of a 100% efﬁcacious vaccine, as the outcome for our CEA. Given a willing-
ness-to-pay threshold, routine pediatric EV71 vaccination would be cost-effective if and only if
EVC < ðWillingness‐to‐pay thresholdÞ  ðHealth utility loss due to EV71‐HFMD per birthÞ
þ Cost due to EV71‐HFMD per birth ð2Þ
We denote this ceiling by EVCmax hereafter. With EVCmax as the outcome of our CEA, we
can easily obtain the cost-effective vaccine cost ceiling of any given vaccine by multiplying
EVCmax by the corresponding vaccine efficacy.
Base Case
We performed the CEA from the societal perspective [19]. Costs and health utility loss were
discounted at 3% per annum [20]. We used one times the gross domestic product per capita
(GDPpc) (US$6,700 in 2013 for China [21]), which is the WHO-CHOICE criterion for very
cost-effective interventions [20], as the societal willingness-to-pay threshold. In terms of
assumptions regarding test-negative cases, we used the most conservative assumptions in the
base case (colored in pink in Fig 2B) in order to avoid overestimating the cost-effectiveness of
vaccination. This corresponded to assuming that (i) the percentage of test-negative cases that
were mild was the same as that for test-positive cases (at the first branching point in Fig 2B)
and (ii) none of the test-negative cases were EV71 (at the second branching point in Fig 2B).
Uncertainty Analysis
We considered all possible combinations of the following decision-making uncertainty associ-
ated with the choices of CEA parameters: (i) inclusion or exclusion of productivity loss of
fatal cases that were EV71 during 2010–2013 (the second branching point; annotated in yellow and blue shades), respectively. The outcomes in the three
scenarios colored in cyan were identical; hence, there were only 19 unique scenarios (labeled A–S). The base case (scenario A) is colored in pink. The sizes
of the wedges illustrate the underlying assumptions and are not proportional to the actual percentages (the differences in serotype and severity distribution
for severe/fatal cases between scenarios would not be apparent otherwise because the number of mild cases was much larger than that of severe/fatal
cases).
doi:10.1371/journal.pmed.1001975.g002
Cost-Effectiveness of EV71 Vaccination in China
PLOSMedicine | DOI:10.1371/journal.pmed.1001975 March 15, 2016 7 / 24
parents or caregivers due to caring for their sick children (i.e., indirect non-medical costs), (ii)
discounting costs and health utility loss at 3% or 6%, and (iii) using one or three times GDPpc
as the willingness-to-pay threshold (the latter is the WHO-CHOICE criterion for cost-effective
interventions [20]). For each combination of these possibilities (no probability distributions
are imposed on these parameters), we calculated EVCmax for all 19 test-negative scenarios in
Fig 2B.
In addition, we considered the uncertainty associated with under-ascertainment and under-
reporting [22]. The validity of our CEA substantially depends on the proportion of
EV71-HFMD cases not registered by national surveillance. To estimate this proportion, we
compared the incidence rate of EV71-HFMD reported in the EV71 vaccine phase III trials (in
which intensive active surveillance for HFMD was conducted in one county of Beijing, six
counties of Jiangsu, and seven counties of Guangxi) with the incidence rate of EV71-HFMD
registered by national surveillance in the counties and time periods of these trials [12–14]. We
estimated the EV71-HFMD incidence rate in each trial using the number of participants and
EV71-associated diseases in the placebo group. See “Estimation of the Unregistered Propor-
tion” in S1 Text for details. We then repeated the calculation of EVCmax in all of the above-
mentioned scenarios assuming that the resulting unregistered proportion was generalizable to
the whole country and that the expected cost and QALY loss of registered and unregistered
cases were similar.
Probabilistic Sensitivity Analysis
In each scenario, we performed probabilistic sensitivity analysis to account for parametric
uncertainty in our estimates of the risk of EV71-HFMD (Pmild, Psevere, Pfatal) and the expected
costs and QALY loss per case due to EV71-HFMD (Cmild, Csevere, Cfatal, Qmild,, Qsevere, Qfatal; see
“Survey on Household Costs and Quality of Life Detriment Associated with EV71-HFMD” in
S1 Text for details). When considering the unregistered proportion in the uncertainty analysis,
we assumed the proportion of EV71-HFMD cases registered by national surveillance followed
a beta distribution that corresponded to the mean and 95% CI obtained from the comparison
of incidence rate between the EV71 vaccine phase III trials and the national surveillance data-
base. See Table 1 for details on the probability distributions used in the probabilistic sensitivity
analysis.
Comparative Cost-Effectiveness Analysis of the Three Vaccines
The three EV71 vaccines have different efficacy estimates, and reliable estimates of their costs
are not yet available. As such, we used EVCmax to identify cost regions where each vaccine
would be preferred given uncertainty in their efficacies. Specifically, because EVC is simply the
cost per unit of vaccine efficacy purchased, it could be used to compare the incremental cost-
effectiveness of any two vaccines as follows (no vaccination is just a special case with US$0 cost
and no efficacy). If vaccines A and B have efficacies εA> εB and their costs are VA> VB,
choosing vaccine A over vaccine B would be cost-effective if and only if (VA − VB)/(εA − εB)<
EVCmax. For each possible combination of costs for the three vaccine candidates, we used this
criterion to identify the candidate that has the highest probability of being the optimal vaccine
by assuming that 1 − vaccine efficacy for the three vaccines followed log-normal distributions
such that the medians and 2.5th and 97.5th percentiles of the associated vaccine efficacies were
the same as the point estimates and 95% CIs of the vaccine efficacies reported in the clinical tri-
als [12–14]. Please see “Comparative CEA of the Three Vaccine Candidates” in S1 Text for
more details.
Cost-Effectiveness of EV71 Vaccination in China
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Results
Base Case
In the base case, the risk that a child would develop mild, severe, and fatal EV71-HFMD
between age 6 mo and 5 y was 3,088 (95% CI 3,084–3,093), 83.4 (95% CI 82.6–84.2), and 3.1
(95% CI 3.0–3.3) per 100,000, respectively (Fig 3A; Table 1). The estimated cost per birth
attributed to EV71-HFMD was US$10.6 (95% CI US$9.7–US$11.5); 74%, 25%, and 1% of this
Table 1. Parameters for the cost-effectivenessmodel.
Description Baseline
Value
Values for
Uncertainty
Analysis
Values for Probabilistic Sensitivity
Analysis
Source
Risk of EV71-HFMD (per
100,000 births)
Dirichlet distribution with parameters
equal to one plus the number of mild,
severe, and fatal cases
National HFMD surveillance database
and virological surveillance records from
31 provinces during 2010–2013. Values
for uncertainty analysis corresponded to
the risk estimates across the 19
scenarios in Fig 2B. Values for
probabilistic sensitivity analysis
corresponded to the conjugate posterior
distributions for multinomial likelihood
assuming that the priors were a non-
informative Dirichlet distribution (all
parameters equal to one).
Mild, Pmild 3,088 2,932–7,077
Severe, Psevere 83 75–107
Fatal, Pfatal 3.13 3.04–3.53
Expected cost due to
EV71-HFMD per birth
including productivity loss
of parents/caregivers
Expected cost and QALY loss in each
severity–region stratum followed bivariate
normal distribution with mean and
covariance matrix shown in S12 Table
Telephone survey of parents/caregivers
of 1,787 laboratory-conﬁrmed
EV71-HFMD pediatric cases. Expected
cost and QALY loss in each severity–
region stratum were estimated using the
central limit theorem.
Mild, Cmild 7.86 —
Severe, Csevere 2.68 —
Fatal, Cfatal 0.08 —
Expected cost due to
EV71-HFMD per birth
excluding productivity loss
of parents/caregivers
Mild, Cmild 6.11 —
Severe, Csevere 2.57 —
Fatal, Cfatal 0.07 —
Expected QALY loss due to
EV71-HFMD per birth
Mild, Qmild 11.2 × 10
−5
—
Severe, Qsevere 1.24 × 10
−5
—
Fatal, Qfatal 95.3 × 10
−5
—
Discount rate for cost and
health utility
3% 3% or 6% — Assumed
Willingness-to-pay
threshold
1 × GDPpc 1 or 3 × GDPpc — Assumed
Proportion of EV71-HFMD
cases registered by national
surveillance
1 1 or 0.74 with
parameter
uncertainty
Beta distribution with mean 0.74 and
standard deviation 0.053
Comparison of the incidence rate of
EV71-HFMD in the three vaccine trials
with that in the national surveillance
doi:10.1371/journal.pmed.1001975.t001
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Fig 3. The risk, expected costs, and health utility loss of EV71-HFMD per birth in the base case. Error
bars indicate 95%CIs. (A) Risk of mild, severe, and fatal EV71-HFMD. The 95%CIs are annotated because
they are not graphically apparent. (B) Expected costs and health utility loss attributable to EV71-HFMD
stratified by severity. To indicate the relative contribution of cost and health utility loss in EVCmax, health utility
loss was expressed in monetary terms as the product of QALY loss and willingness-to-pay threshold, which is
set at one times GDPpc (US$6,700). (C) Percentage breakdown of EVCmax.
doi:10.1371/journal.pmed.1001975.g003
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cost was incurred by mild, severe, and fatal cases, respectively (Fig 3B). Pediatric EV71 vaccina-
tion would be cost-saving if EVC was below this amount.
The expected QALY loss attributed to EV71-HFMD per 10,000 births was 10.8 (10.7–10.9);
89%, 10%, and 1% of this loss was incurred by fatal (almost entirely due to premature death),
mild, and severe cases, respectively (Fig 3B). With a willingness-to-pay threshold of one times
GDPpc, pediatric EV71 vaccination was cost-effective if EVC was below US$17.9 (US$16.9–US
$18.8). The reduction in costs and averted QALY loss (in monetary terms) constituted 60%
and 40% of the net monetary benefit of vaccination, respectively (Fig 3C).
Uncertainty Scenarios
Mild cases were a major constituent of EVCmax (Fig 3C), and the risk of mild EV71-HFMD,
and hence EVCmax, strongly depended on the percentage of test-negative mild cases that were
EV71 (Table 2; Fig 4A and 4B). In contrast, EVCmax was relatively insensitive to the percentage
of test-negative severe/fatal cases that were EV71 because (i) severe cases were only a minor
constituent of EVCmax (Fig 3C) and the risk of severe EV71-HFMD varied less across scenarios
(Fig 4C), and (ii) although fatal cases were a major constituent of EVCmax (Fig 3C), the risk of
fatal EV71-HFMD was almost constant across scenarios (Fig 4D). Compared to EVCmax in the
base case (which was the lowest and hence the most conservative among all scenarios), EVCmax
increased by (i) 19%–32% if the percentage of test-negative mild cases that were EV71 was the
same as that for test-positive mild cases (scenarios K, B, E, H, and P in Tables 2 and S5 and Fig
4A) and (ii) 50%–67% if all test-negative mild cases were EV71 (scenarios L, C, N, Q, F, I, and
S in Tables 2 and S5 and Fig 4A).
When productivity loss of parents/caregivers was excluded, EVCmax was 10%–14% lower
(Tables 2 and S5; S2 Fig). EVCmax was very sensitive to the willingness-to-pay threshold.
Increasing the threshold from one to three times GDPpc increased EVCmax by 58%–84%
(Tables 2 and S5; S2 Fig).
EVCmax was sensitive to discount rate because QALY loss due to pediatric premature death—
which was the major driver for health utility loss and a major constituent of EVCmax (Fig 3B and
3C)—was very sensitive to the discount rate. Increasing the discount rate for cost and health util-
ity from 3% to 6% reduced EVCmax by around 14%–19% (Tables 2 and S5; S2 Fig).
We estimated that the aggregated incidence rate of EV71-HFMD in the EV71 vaccine phase
III trials and the corresponding rate in national surveillance were 18.3 (95% CI 16.3–20.6) and
13.4 (95% CI 12.4–14.5) per 1,000 person-years, respectively. These estimates suggest that only
74% (95% CI 64%–84%) of EV71-HFMD cases in these areas were registered by national sur-
veillance during the trial periods. If this proportion is generalizable to the whole country and
the expected cost and QALY loss of registered and unregistered cases are similar, then EVCmax
is increased by 36% (95% CI 23%–50%) (Tables 2 and 3; S3 Fig).
The efficacy estimates for the vaccines made by Beijing Vigoo Biological, Sinovac Biotech,
and the Chinese Academy of Medical Sciences (CAMS) were 90% (95% CI 67.1%–96.9%),
94.8% (95% CI 87.2%–97.9%), and 97.4% (95% CI 92.9%–99%), respectively [12–14]. Using
the base-case EVCmax, we estimated that EV71 vaccination would be cost-effective in China if
the vaccine cost was below US$12.0–US$17.7, US$15.3–US$18.0, and US$16.2– US$18.3 for
the Beijing Vigoo Biological, Sinovac Biotech, and CAMS vaccines, respectively, when com-
pared to no vaccination. Fig 5 indicates the optimal vaccine given any combination of the costs
for the three vaccines within these ranges. For example, if all three vaccines were priced at the
point estimate of EVCmax × vaccine efficacy (which corresponds to US$16.1, US$17.0, and US
$17.4 for the Beijing Vigoo Biological, Sinovac Biotech, and CAMS vaccine, respectively), then
the CAMS vaccine would be optimal.
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Discussion
Our CEA suggests that routine pediatric EV71 vaccination in China would be very cost-effec-
tive if the all-inclusive EVC (including all logistical, procurement, and administration costs
needed to confer 5 y of vaccine protection) is below US$17.9 (95% CI US$16.9–US$18.8).
Compared to no vaccination, routine pediatric EV71 vaccination would be cost-effective in
China if the vaccine cost is below US$12.0–US$17.7, US$15.3–US$18.0, and US$16.2–US$18.3
Table 2. Cost-effectiveness ceiling on effective vaccine cost if all EV71-HFMD cases were registered by the national HFMD surveillance.
Scenario Societal Perspective Excluding Productivity Loss of Parents/Caregivers
3% Discounting 6% Discounting 3% Discounting 6% Discounting
WTP
1 × GDPpc
WTP
3 × GDPpc
WTP
1 × GDPpc
WTP
3 × GDPpc
WTP
1 × GDPpc
WTP
3 × GDPpc
WTP
1 × GDPpc
WTP
3 × GDPpc
A (base
case)
17.9 (16.9–
18.8)
32.4 (31.0–
33.7)
14.6 (13.7–
15.4)
23.5 (22.5–
24.6)
16.0 (15.2–
16.8)
30.5 (29.3–
31.7)
12.8 (12.1–
13.5)
21.7 (20.8–
22.7)
B 22.0 (20.6–
23.3)
37.2 (35.5–
38.8)
18.5 (17.2–
19.7)
28.1 (26.7–
29.5)
19.3 (18.2–
20.4)
34.5 (33.0–
36.0)
15.9 (14.9–
16.9)
25.5 (24.3–
26.7)
C 28.1 (26.2–
29.9)
44.4 (42.3–
46.6)
24.3 (22.5–
26.0)
34.9 (33.0–
36.9)
24.1 (22.6–
25.6)
40.5 (38.6–
42.3)
20.5 (19.1–
21.9)
31.2 (29.5–
32.8)
D 19.0 (18.1–
20.0)
34.7 (33.4–
36.1)
15.4 (14.6–
16.3)
25.1 (24.0–
26.2)
17.1 (16.3–
17.9)
32.8 (31.6–
34.1)
13.7 (12.9–
14.4)
23.3 (22.3–
24.3)
E 23.1 (21.8–
24.4)
39.5 (37.9–
41.2)
19.3 (18.1–
20.6)
29.7 (28.2–
31.1)
20.4 (19.3–
21.5)
36.8 (35.3–
38.3)
16.7 (15.7–
17.8)
27.1 (25.8–
28.3)
F 29.2 (27.4–
31.1)
46.8 (44.6–
49.0)
25.1 (23.4–
26.9)
36.5 (34.6–
38.5)
25.2 (23.7–
26.8)
42.8 (40.9–
44.7)
21.4 (19.9–
22.8)
32.7 (31.1–
34.4)
G 19.3 (18.4–
20.3)
35.4 (34.1–
36.8)
15.7 (14.8–
16.6)
25.6 (24.5–
26.6)
17.5 (16.6–
18.3)
33.5 (32.3–
34.8)
13.9 (13.2–
14.7)
23.8 (22.8–
24.7)
H 23.4 (22.1–
24.8)
40.2 (38.6–
41.9)
19.6 (18.4–
20.8)
30.1 (28.7–
31.5)
20.7 (19.6–
21.8)
37.5 (36.0–
39.0)
17.0 (16.0–
18.0)
27.5 (26.3–
28.8)
I 29.6 (27.7–
31.4)
47.5 (45.3–
49.7)
25.4 (23.7–
27.1)
37.0 (35.1–
38.9)
25.6 (24.0–
27.1)
43.5 (41.6–
45.4)
21.6 (20.2–
23.0)
33.2 (31.5–
34.8)
J 18.1 (17.0–
19.1)
32.3 (30.9–
33.6)
14.8 (13.9–
15.8)
23.6 (22.5–
24.7)
16.1 (15.2–
17.0)
30.3 (29.0–
31.6)
13.0 (12.2–
13.8)
21.8 (20.8–
22.8)
K 21.5 (20.2–
22.8)
36.3 (34.7–
38.0)
18.1 (16.9–
19.3)
27.5 (26.1–
28.9)
18.8 (17.7–
19.9)
33.6 (32.2–
35.1)
15.5 (14.5–
16.5)
24.9 (23.7–
26.1)
L 26.9 (25.1–
28.7)
42.7 (40.6–
44.8)
23.2 (21.5–
24.8)
33.5 (31.7–
35.4)
23.0 (21.6–
24.5)
38.9 (37.1–
40.7)
19.6 (18.2–
20.9)
29.9 (28.3–
31.5)
M 19.7 (18.6–
20.7)
35.5 (34.0–
36.9)
16.1 (15.1–
17.0)
25.8 (24.7–
26.9)
17.7 (16.8–
18.6)
33.5 (32.2–
34.8)
14.2 (13.4–
15.0)
23.9 (22.9–
25.0)
N 28.5 (26.7–
30.2)
45.9 (43.8–
48.0)
24.4 (22.8–
26.1)
35.7 (33.8–
37.6)
24.6 (23.2–
26.0)
42.1 (40.2–
43.9)
20.8 (19.4–
22.1)
32.1 (30.5–
33.6)
O 20.1 (19.1–
21.2)
36.4 (34.9–
37.8)
16.4 (15.5–
17.4)
26.4 (25.3–
27.6)
18.1 (17.2–
19.0)
34.4 (33.0–
35.7)
14.5 (13.7–
15.4)
24.5 (23.5–
25.6)
P 23.6 (22.2–
24.9)
40.4 (38.8–
42.1)
19.7 (18.4–
20.9)
30.3 (28.8–
31.7)
20.8 (19.7–
21.9)
37.7 (36.2–
39.2)
17.1 (16.0–
18.1)
27.7 (26.4–
28.9)
Q 28.9 (27.2–
30.7)
46.8 (44.7–
49.0)
24.8 (23.1–
26.4)
36.3 (34.5–
38.2)
25.1 (23.6–
26.5)
42.9 (41.1–
44.8)
21.1 (19.8–
22.4)
32.6 (31.1–
34.2)
R 18.6 (17.7–
19.5)
34.2 (32.9–
35.5)
15.0 (14.2–
15.8)
24.6 (23.6–
25.6)
16.7 (16.0–
17.5)
32.4 (31.2–
33.6)
13.3 (12.6–
14.0)
22.9 (21.9–
23.8)
S 29.7 (27.8–
31.6)
47.4 (45.1–
49.6)
25.6 (23.8–
27.4)
37.1 (35.1–
39.1)
25.6 (24.1–
27.2)
43.3 (41.3–
45.2)
21.7 (20.3–
23.2)
33.2 (31.5–
34.9)
The mean and 95% CI of EVCmax are listed for each scenario.
WTP, willingness-to-pay threshold.
doi:10.1371/journal.pmed.1001975.t002
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for the Beijing Vigoo Biological, Sinovac Biotech, and CAMS vaccines, respectively. Given any
combination of the costs for the three vaccines within these ranges, policymakers can use Fig 5
to determine the optimal vaccine.
Our estimates of cost-effective vaccine cost ceiling are very conservative for the following
reasons. First, we have likely underestimated the true disease burden of EV71, and hence EVC-
max, because (i) EV71 can cause diseases other than HFMD [9] and (ii) underreporting and
under-ascertainment of EV71-HFMD, as we have demonstrated, might be substantial (Tables
2 and 3; S2 and S3 Figs).
Second, we assumed that EV71 vaccination had no effect in reducing the severity of
EV71-HFMD because there were too few severe cases in the phase III trials to provide robust
evidence for such efficacy [12–14]. If EV71 vaccines, like many other vaccines such as rotavirus
vaccines [23], can reduce disease severity, then we have underestimated EVCmax.
Third, we used one times GDPpc as the base-case willingness-to-pay threshold, in keeping
with the WHO-CHOICE criterion for very cost-effective interventions [20]. The commonly
Fig 4. Cost-effectiveness of routine pediatric EV71 vaccination in China with a willingness-to-pay threshold of one times GDPpc. The 21 scenarios
from Fig 2 are listed along the x-axis in ascending order of EVCmax. The base case was scenario A, which had the lowest EVCmax. The color shades at the
bottom indicate the assumptions regarding the percentage of test-negative cases that were mild during 2010–2012 (bottom row), the percentage of test-
negative severe/fatal cases that were EV71-HFMD (middle row), and the percentage of test-negative mild cases that were EV71-HFMD (top row) in each
scenario, where darker shades correspond to higher percentages. As described in Fig 2B, three combinations of these percentages resulted in the same
scenario, namely scenario E. The size of the 95% prediction intervals was driven by the parametric uncertainty associated with our estimates of the risk of
EV71-HFMD and the mean cost and QALY loss attributed to EV71-HFMD in our probability sensitivity analysis (as in Fig 2B). (A) Pediatric EV71 vaccination
would be cost-saving and cost-effective if EVC was below the cost of EV71-HFMD (blue bars) and EVCmax (blue plus green bars), respectively. (B–D) The
risk of mild, severe, and fatal EV71-HFMD in each scenario. The error bars show the 95% CIs, but in some cases they are not apparent for the risk of mild and
severe EV71-HFMD.
doi:10.1371/journal.pmed.1001975.g004
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used thresholds in high-income countries, such as the UK (£20,000–£30,000) [24], are close to
one times GDPpc. WHO-CHOICE classifies interventions as cost-effective if the ICER is
between one and three times GDPpc. This range of willingness-to-pay threshold might also be
suitable for China, which is a middle-income country with a rapidly increasing GDPpc. As
shown, EVCmax would increase by 60%–80% if the threshold was three times GDPpc (S2 Fig).
Table 3. Cost-effectiveness ceiling on effective vaccine cost if the proportion of EV71-HFMD cases registered by national surveillance was the
same as that observed in the three EV71 vaccine trials.
Scenario Societal Perspective Excluding Productivity Loss of Parents/Caregivers
3% Discounting 6% Discounting 3% Discounting 6% Discounting
WTP
1 × GDPpc
WTP
3 × GDPpc
WTP
1 × GDPpc
WTP
3 × GDPpc
WTP
1 × GDPpc
WTP
3 × GDPpc
WTP
1 × GDPpc
WTP
3 × GDPpc
A (base
case)
24.4 (20.9–
28.2)
44.1 (38.1–
50.9)
19.9 (17.0–
23.1)
32.1 (27.6–
37.1)
21.8 (18.8–
25.2)
41.6 (35.9–
48.0)
17.5 (15.0–
20.3)
29.6 (25.6–
34.3)
B 29.9 (25.7–
34.7)
50.7 (43.7–
58.5)
25.2 (21.5–
29.3)
38.3 (32.9–
44.3)
26.2 (22.5–
30.4)
47.0 (40.5–
54.2)
21.7 (18.5–
25.2)
34.8 (30.0–
40.2)
C 38.3 (32.7–
44.5)
60.5 (52.1–
70.0)
33.1 (28.2–
38.6)
47.6 (40.9–
55.2)
32.9 (28.1–
38.2)
55.1 (47.5–
63.7)
28.0 (23.9–
32.6)
42.5 (36.5–
49.2)
D 25.9 (22.3–
30.0)
47.3 (40.9–
54.7)
21.1 (18.1–
24.4)
34.2 (29.5–
39.5)
23.3 (20.1–
27.0)
44.8 (38.6–
51.6)
18.6 (16.0–
21.6)
31.8 (27.4–
36.7)
E 31.5 (27.0–
36.5)
53.9 (46.4–
62.2)
26.3 (22.5–
30.6)
40.4 (34.7–
46.7)
27.8 (23.8–
32.2)
50.2 (43.3–
57.9)
22.8 (19.5–
26.5)
36.9 (31.7–
42.7)
F 39.8 (34.0–
46.4)
63.8 (54.8–
73.8)
34.2 (29.2–
40.0)
49.8 (42.7–
57.7)
34.4 (29.5–
40.0)
58.3 (50.2–
67.4)
29.1 (24.8–
33.9)
44.6 (38.3–
51.7)
G 26.4 (22.7–
30.6)
48.3 (41.6–
55.8)
21.4 (18.4–
24.8)
34.8 (30.0–
40.3)
23.8 (20.5–
27.5)
45.7 (39.5–
52.8)
19.0 (16.3–
22.0)
32.4 (27.9–
37.4)
H 32.0 (27.4–
37.1)
54.9 (47.2–
63.4)
26.7 (22.8–
31.1)
41.1 (35.3–
47.6)
28.2 (24.2–
32.7)
51.2 (44.1–
59.1)
23.2 (19.8–
26.9)
37.6 (32.3–
43.4)
I 40.3 (34.4–
46.9)
64.8 (55.7–
74.9)
34.6 (29.5–
40.4)
50.4 (43.3–
58.5)
34.9 (29.9–
40.5)
59.3 (51.1–
68.6)
29.5 (25.1–
34.3)
45.3 (38.9–
52.4)
J 24.6 (21.1–
28.6)
44.0 (38.0–
50.8)
20.2 (17.3–
23.5)
32.2 (27.7–
37.2)
22.0 (18.9–
25.5)
41.3 (35.7–
47.7)
17.7 (15.2–
20.6)
29.7 (25.6–
34.3)
K 29.3 (25.1–
34.0)
49.5 (42.7–
57.2)
24.6 (21.0–
28.7)
37.4 (32.1–
43.3)
25.6 (22.0–
29.7)
45.8 (39.5–
53.0)
21.2 (18.1–
24.6)
34.0 (29.2–
39.3)
L 36.6 (31.3–
42.7)
58.2 (50.1–
67.5)
31.6 (27.0–
36.9)
45.7 (39.2–
53.0)
31.4 (26.9–
36.5)
53.0 (45.6–
61.3)
26.6 (22.7–
31.1)
40.7 (35.0–
47.3)
M 26.8 (23.0–
31.0)
48.4 (41.7–
55.8)
21.9 (18.8–
25.4)
35.2 (30.3–
40.6)
24.1 (20.7–
27.9)
45.7 (39.4–
52.7)
19.3 (16.6–
22.5)
32.6 (28.1–
37.7)
N 38.8 (33.2–
45.2)
62.7 (53.9–
72.4)
33.3 (28.4–
38.8)
48.7 (41.8–
56.4)
33.6 (28.7–
38.9)
57.4 (49.4–
66.2)
28.3 (24.2–
32.9)
43.7 (37.6–
50.5)
O 27.4 (23.5–
31.8)
49.6 (42.8–
57.3)
22.4 (19.2–
26.0)
36.0 (31.0–
41.6)
24.7 (21.3–
28.6)
46.9 (40.5–
54.1)
19.8 (17.0–
23.0)
33.4 (28.8–
38.6)
P 32.1 (27.6–
37.2)
55.1 (47.5–
63.6)
26.8 (23.0–
31.2)
41.2 (35.5–
47.7)
28.4 (24.3–
32.9)
51.4 (44.3–
59.4)
23.3 (19.9–
27.0)
37.7 (32.4–
43.5)
Q 39.5 (33.8–
45.8)
63.9 (55.0–
73.8)
33.8 (28.9–
39.3)
49.5 (42.6–
57.4)
34.2 (29.3–
39.6)
58.6 (50.5–
67.6)
28.8 (24.6–
33.4)
44.5 (38.3–
51.4)
R 25.3 (21.8–
29.3)
46.6 (40.2–
53.8)
20.5 (17.6–
23.7)
33.5 (28.9–
38.7)
22.8 (19.7–
26.4)
44.2 (38.1–
51.0)
18.1 (15.6–
21.0)
31.2 (26.9–
36.0)
S 40.5 (34.6–
47.1)
64.6 (55.5–
74.6)
34.9 (29.7–
40.7)
50.6 (43.3–
58.6)
35.0 (29.9–
40.6)
59.0 (50.8–
68.2)
29.6 (25.3–
34.5)
45.3 (38.9–
52.4)
The mean and 95% CI of EVCmax are listed for each scenario.
WTP, willingness-to-pay threshold.
doi:10.1371/journal.pmed.1001975.t003
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Fig 5. Comparative cost-effectiveness analysis of the three vaccine candidates based on the base-
case EVCmax. The color coding indicates the optimal vaccine given the costs of the three vaccines (VVigoo,
VSinovac, VCAMS).
doi:10.1371/journal.pmed.1001975.g005
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On the other hand, there have been ongoing discussions about the appropriateness of the
WHO-CHOICE thresholds, and some preliminary work suggests a real-world threshold of
around 0.18–0.71 times GDPpc in middle- and high-income countries [25]. As an illustration,
adopting a threshold of 0.5 times GDPpc would reduce EVCmax by around 25%.
Finally, we did not account for productivity loss due to pediatric premature death because
of unresolved debate about the way such losses should be costed [18]. Including this productiv-
ity loss would increase EVCmax.
Our study has several limitations. First, we have presented our CEA results using EVC, an
outcome with which readers may be less familiar compared to other outcomes commonly used
in health economic evaluation, such as ICERs. The calculation underlying EVC, however, is the
same as that for evaluating the incremental net monetary benefits of vaccination. We used
EVC as the outcome because (i) health policymakers in China are currently most interested in
the vaccine cost ceiling that would render routine pediatric EV71 vaccination cost-effective in
order to prepare for a potential future addition to the Expanded Programme on Immunization
and price negotiation with the vaccine manufacturers, and (ii) the reported vaccine efficacy
and associated uncertainty for the three EV71 vaccine candidates are significantly different. As
such, EVC, which is simply the vaccine cost adjusted for the corresponding vaccine efficacy,
provides a succinct way of defining the vaccine cost ceiling without the need to reference the
efficacy of any particular vaccine. As we have shown, EVC can be easily used to compare the
cost-effectiveness of the three vaccine candidates, which have significantly different vaccine
efficacy and hence vaccine cost ceilings.
Second, we have not accounted for the potential impact of an increase in the age of infection
caused by herd immunity or limited duration of vaccine protection. Our previous study
showed that the severity of EV71-HFMD decreases substantially with age [6]. Therefore, the
cost-effectiveness of pediatric vaccination would be only slightly reduced if some of the burden
averted by vaccination among children under 5 y is offset by increased infection in older age
groups.
Third, we used self-reported hospital charges as a proxy for the opportunity cost of care,
because of the difficulty of accessing hospital records across the entire country. Several studies
have estimated the economic cost of HFMD treatment in single cities or counties in China
using hospital records [26–34]. However, only two of these, one set in Ningbo in Zhejiang and
the other in seven cities in Shandong, reported mean costs using hospital records and the same
severity stratification as the national surveillance database [29,34]. The Ningbo study reported
mean costs of US$161, US$530, and US$1,262, respectively, for mild outpatient, mild inpatient,
and severe cases, whereas the estimates in the Shandong study were US$124, US$699, and US
$2,076, respectively. In comparison, the corresponding costs in our study for the east region of
China (where Ningbo and Shandong are located) were US$239, US$1,011, and US$3,592. The
costs for mild cases in these two studies and ours differ by less than 48%, which suggests that
our estimate of EVCmax should be reasonably robust because mild cases are the main cost
driver (Fig 3C) and our CEA assumptions are very conservative.
Fourth, we modified the EuroQol EQ-5D-3L instument to elicit quality of life of children
younger than 7 y, as has been done previously in similar studies [35]. Although such modifica-
tions have not been validated, the associated uncertainty had little effect on our results because
89% of QALY loss due to EV71-HFMD came from premature death (Fig 3C).
Fifth, we assumed that the cost and health utility loss estimates based on laboratory-con-
firmed EV71-HFMD cases were representative of all EV71-HFMD cases.
Sixth, we assumed that the long-term average risk of EV71-HFMD in the future would be
similar to that registered by national surveillance during 2010–2013. Year-to-year variations in
EV71-HFMD burden can be significant, and future EV71-HFMD epidemiology may not be
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congruent with this assumption. The confidence intervals associated with our estimates of
EVCmax do not reflect possible deviations of future EV71-HFMD burden from the long-term
average that we have assumed. For example, if future long-term EV71-HFMD were more simi-
lar to that in 2012 or 2013, which were the years with the highest and lowest EV71-HFMD bur-
den, then EVCmax would be increased by 42% and decreased by 47%, respectively.
Finally, our analysis assumed that no alternative preventive interventions are available to be
used that could also reduce the burden of EV71-HFMD. If such interventions exist, this may
affect the cost-effectiveness of vaccination. We conducted a literature review of the potential
effectiveness of alternative interventions to prevent the spread of EV71 (see “Under What Con-
ditions Would We Not Vaccinate Because a More Cost-Effective Alternative Intervention
Exists?” in S1 Text for details). The review found only one relevant article, which suggested
that the extreme infection control measures imposed during the 2003 SARS outbreak in Hong
Kong reduced the incidence of HFMD by 57.2%. However, these reactive control measures,
which involved territory-wide school closure, hand and respiratory hygiene awareness cam-
paigns, and disinfection, are unlikely to be reproducible for prolonged periods outside a pan-
demic or highly urbanized setting. Nevertheless, if such a level of reduction in HFMD
incidence is achievable without using vaccination, then EVCmax would be reduced by 57.2% to
US$7.3.
To our knowledge, this is the first economic evaluation of EV71 vaccination since the EV71
vaccine phase III trial results were published in 2013–2014. In 2010, Lee et al. [36] used the
national surveillance data from 2007–2009 and extrapolated US health care cost figures to
China to forecast that with a willingness-to-pay to avert a disability-adjusted life year of three
times GDPpc, pediatric EV71 vaccination would be cost-effective from a third-party payer per-
spective if vaccine cost per individual was US$25 and vaccine efficacy was70% [36]. The
assumed risk of EV71-HFMD in their study (0.04%–1%) was much lower than in ours (3%–
8%; Fig 4B) because the disease burden registered by national surveillance has increased sub-
stantially since 2009. In their sensitivity analysis, Lee et al. found that when the risk of EV71-as-
sociated diseases was 5% (i.e., similar to that in the intermediate scenarios in Fig 4B), pediatric
EV71 vaccination would be cost-saving if vaccine cost was US$50 and vaccine efficacy was 80%
(i.e., an EVC of US$63). In contrast, pediatric EV71 vaccination would be cost-saving in the
corresponding scenarios of our study only if EVC< US$12.2 (S2 Fig). Therefore, the discrep-
ancies between the two studies are also due to differences in cost estimates.
Our study is also the first to our knowledge to highlight that the current practice of omitting
test-negative results generates substantial uncertainty regarding the burden of EV71-HFMD
(Fig 4B). Laboratory surveillance is the cornerstone for monitoring diseases caused by multiple
strains of pathogens, such as HFMD, pneumococcal diseases, etc. In our base case (in which we
assumed that none of the test-negative cases were EV71-HFMD), EV71 accounted for 26.0%
and 64.3% of mild and severe/fatal HFMD cases, respectively, in China during 2010–2013. Pol-
icymakers can regard this as the maximal proportion of HFMD burden that is preventable by
routine pediatric EV71 vaccination. If routine pediatric EV71 vaccination is implemented and
vaccine coverage is high, robust laboratory surveillance of HFMD-causing enteroviruses will be
critical for monitoring vaccine impact as well as investigating herd immunity, cross-protection,
and serotype replacement (e.g., as demonstrated for pneumococcal conjugate vaccination
[16,37,38]).
Our current and previous study [6] suggest that there are large geographical variations in
the risk of EV71-HFMD (S4 Fig). Such variations are likely due to geographical differences in
underlying epidemiologic factors, underreporting, and health care quality. If national, popula-
tion-wide rollout is infeasible in the initial stages of routine pediatric EV71 vaccination, policy-
makers could consider prioritizing areas in which EV71 vaccination is most cost-effective.
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EV71 vaccine trials, i.e., 74%(95% CI 64%–84%). See “Estimation of the Unregistered Propor-
tion” in S1 Text and S15 Table for details.
(EPS)
S4 Fig. Geographical variation in the risk and severity of EV71-HFMD among children
under the age of 5 y in China. (A–C) Risk of mild, severe, and fatal cases of EV71-HFMD.
(D–F) Case severity, case fatality, and severity–fatality risk.
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S5 Fig. The distributions of costs and QALY loss per episode of EV71-HFMD in the survey
stratified by severity and geographical region. (A) Costs. (B) QALY loss during illness. In
each box, the central mark is the median, the edges of the box are the 25th and 75th percentiles,
the whiskers extend to the extreme data points not considered outliners, and outliners are plot-
ted individually with “+”marks. Data points are considered outliners if they are larger than q75
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75th percentiles.
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Editors' Summary
Background
Since 2007, outbreaks of hand, foot, and mouth disease (HFMD)—a contagious infection
that mainly affects young children—have been occurring annually in China. Between 2010
and 2014, China accounted for 9.8 million of the 11.3 million cases of HFMD reported to
the World Health Organization (WHO); in 2012, HFMD was the leading notifiable disease
in China among children under five years old. HFMD is caused by a group of viruses called
enteroviruses that are transmitted through contact with the mucus produced when an
infected individual coughs or sneezes, through contact with the feces of an infected person,
and through contact with contaminated surfaces. Good hygiene and frequent handwash-
ing can reduce the spread of HFMD. The characteristic symptoms of HFMD are a non-
itchy red rash with blisters on the hands and feet and painful mouth ulcers. There is no
cure for HFMD, and most infected children get better within 7–10 days. However, some
individuals develop potentially fatal complications such as encephalitis (infection and
inflammation of the brain).
WhyWas This Study Done?
In China, enterovirus 71 (EV71) causes most laboratory-confirmed fatal cases of HFMD.
Routine vaccination against EV71 during the first few months of life might therefore be
one way to reduce China’s HFMD burden. In clinical trials, three inactivated monovalent
EV71 vaccines made in China were shown to be safe and highly efficacious against EV71-
associated HFMD (inactivated monovalent vaccines contain a single virus strain that can-
not replicate; exposure to the vaccine “primes” the immune system to respond quickly
when challenged with live virus, thereby preventing infection with that virus). However,
before implementing routine EV71 vaccination, it is important to know whether this inter-
vention is a good value for the money it would cost. For example, how much money needs
to be spent on vaccination to save one life? In this cost-effectiveness analysis (a study that
estimates the costs and health effects of a medical intervention), the researchers assess the
value for money of routine vaccination of young children against EV71 in China.
What Did the Researchers Do and Find?
The researchers characterized the health and economic burden of EV71-associated HFMD
in China using the national surveillance database, HFMD laboratory test results, and infor-
mation on household costs and health utility loss associated with HFMD cases (health util-
ity is a number that is assigned to a state of health; perfect health and death have utility
values of 1 and 0, respectively) collected in a caregiver survey. They then used a mathemat-
ical model to estimate the effective vaccine cost (EVC; vaccine cost divided by efficacy)
below which routine pediatric vaccination would be cost-effective; WHO defines a cost-
effective intervention as one in which the incremental cost-effectiveness ratio (the incre-
mental costs of introducing an intervention divided by the incremental benefits accrued
by that introduction) is between one and three times the country’s gross domestic product
(GDP) per capita. Routine pediatric vaccination was cost-effective in the researchers’ base-
case analysis—which assumed a willingness-to-pay threshold of one times GDP per capita
—if the EVC was below US$17.9. Increasing the willingness-to-pay threshold to three
times GDP per capita increased the EVC below which routine vaccination would be cost-
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effective by 58%–84%, whereas excluding consideration of the productivity loss of parents/
caregivers while caring for a child with HFMD reduced the EVC below which routine vac-
cination would be cost-effective by 10%–14%.
What Do These Findings Mean?
The validity of these findings depends on the assumptions included in the mathematical
model and on the accuracy of the data fed into the model. However, routine pediatric
EV71 vaccination remained cost-effective at broadly similar EVCs in sensitivity analyses
in which the assumptions built into the model were altered. Overall, these findings suggest
that routine pediatric EV71 vaccination would be very cost-effective in China provided the
cost of immunization (including the cost of the vaccine and all the logistical and adminis-
tration costs of vaccination) is below between US$12.0 and US$18.3 per vaccination;
because the different vaccines have different efficacies, the exact value depends on which
vaccine is used for vaccination. Thus, with 16 million births each year, the annual costs for
routine pediatric EV71 vaccination in China should not exceed US$192–US$293 million.
Importantly, when combined with the findings of a previous study in which the same
researchers showed large geographical variations in the risk of EV71-associated HFMD
across China, these findings can help policymakers identify those regions in China where
EV71 vaccination is likely to be most cost-effective.
Additional Information
This list of resources contains links that can be accessed when viewing the PDF on a device
or via the online version of the article at http://dx.doi.org/10.1371/journal.pmed.1001975.
• A PLOS Medicine Research Article by Takahashi et al. provides information about the
patterns of HFMD outbreaks in China
• The US Centers for Disease Control and Prevention provides information on hand, foot,
and mouth disease (in English and Spanish), including a podcast on the condition
• The UK National Health Service Choices website provides detailed information on
hand, foot, and mouth disease
• Further information about hand, foot, and mouth disease is provided by the World
Health Organization (including up-to-date HFMD surveillance reports from China), the
Nemours Foundation (in English and Spanish), and MedlinePlus (in English and
Spanish)
• AWHO guide on cost-effectiveness analysis is available
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